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Use of Gentamicin as an Alternative Treatment for Gonorrhea
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A high gonorrhoea disease burden, increasing rates, and growing antimicrobial resistance 
portend a developing global public health crisis [1]. Gonorrhea can cause reproductive 
complications such as pelvic inflammatory disease and infertility, blindness in infants born 
to infected mothers, and can facilitate HIV acquisition and transmission. Effective treatment 
prevents sequelae and transmission. Yet Neisseria gonorrhoeae has developed resistance to 
each antimicrobial used for treatment [2]. Development of new antimicrobials has not kept 
pace.
Ceftriaxone is the only remaining recommended agent that reliably cures gonorrhea at all 
anatomic sites.[3] Declining cephalosporin susceptibility in the USA and elsewhere during 
2009–12 raised concern about emerging ceftriaxone resistance [2]; in response, strategies to 
prolong ceftriaxone effectiveness included recommendations for use of ceftriaxone rather 
than oral cephalosporins (based on pharmacokinetic principles and site-specific differences 
in treatment efficacy) and combination therapy to potentially mitigate resistance [3]. 
Concerningly, azithromycin susceptibility has now declined in many countries [4]. A 
ceftriaxone- and azithromycin-resistant strain of N. gonorrhoeae was recently identified in 
the UK, and international transmission of a different ceftriaxone-resistant strain was recently 
described [5,6].
Although ceftriaxone remains effective in the USA, the threat of ceftriaxone resistance and 
challenge of treating cephalosporin-allergic patients necessitate the search for additional 
treatments. Results of phase 2 trials of new antimicrobials (gepotidacin and zoliflodacin) are 
encouraging [7,8], but commercial availability of these agents is not imminent. If ceftriaxone 
is not an option, identification of existing drugs that are effective and well-tolerated is 
needed. We previously investigated available drugs for gonorrhea treatment; one regimen 
was gentamicin 240 mg intramuscularly plus azithromycin 2 g orally [9]. Cure was based on 
negative cultures 10–17 days post-treatment. The gentamicin-based regimen demonstrated 
100% efficacy for urogenital gonorrhoea in a group of 202 patients. Extragenital infections 
were cured, but the sample only included 10 participants with pharyngeal gonorrhea and one 
with rectal gonorrhea. Likely owing to the 2 g azithromycin dose, 56 (26%) participants in 
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the gentamicin arm had mild to moderate nausea and 15 (7%) had mild to moderate 
vomiting. Among all participants who received gentamicin and azithromycin, ten (3%) 
vomited within 1 h. Subsequently, US Centers for Disease Control and Prevention’s 2015 
treatment guidelines listed gentamicin and azithromycin combination therapy as an 
alternative option in the presence of cephalosporin allergy but noted that gastrointestinal 
intolerability might limit use.[3]
In the Lancet, Jonathan Ross and colleagues advance our understanding of the potential 
utility of gentamicin.[10] 720 participants with uncomplicated gonorrhoea were randomly 
assigned to 500 mg of intramuscular ceftriaxone or 240 mg of intramuscular gentamicin; all 
participants received azithromycin 1 g orally. The primary outcome was clearance of N. 
gonorrhoeae by negative nucleic acid amplification testing (NAAT) 2 weeks post treatment. 
409 participants had genital gonorrhoea (219 in the gentamicin group), 256 participants had 
pharyngeal gonorrhoea (128 in the gentamicin group), and 306 had rectal gonorrhoea (147 
in the gentamicin group). At 2 weeks after treatment, infection had cleared for 299 (98%) of 
306 participants in the ceftriaxone group compared with 267 (91%) of 292 participants in 
the gentamicin group (adjusted risk difference −6.4%, 95% CI −10.4% to −2.4%). Similarly, 
151 (98%) of 154 participants with genital gonorrhoea were cleared of infection compared 
with 163 (94%) of 174 participants with genital gonorrhoea in the gentamicin group 
(adjusted risk difference −4.4%, −8.7 to 0). For participants with a pharyngeal infection, a 
greater proportion receiving ceftriaxone had clearance at follow-up (108 [96%] in the 
ceftriaxone group compared with 82 [80%] in the gentamicin group; adjusted risk difference 
−15.3%, −24.0 to −6.5). For participants with rectal infection, clearance at follow-up was 
also greater in the ceftriaxone group (134 [98%] in the ceftriaxone group compared with 107 
[90%] in the gentamicin group; adjusted risk difference −7.8%, −13.6 to −2.0). Thus, 
efficacy of gentamicin for the treatment of gonorrhoea was inferior to efficacy of 
ceftriaxone. When recommending regimens, gonorrhea treatment guidelines have 
traditionally used efficacy estimates of individual agents [11]. Gentamicin efficacy in this 
trial might have been higher had culture rather than NAAT, been used for treatment outcome. 
Additionally, some apparent treatment failures might have been reinfections; 47 (16%) 
participants in the gentamicin arm reported interim condomless sex[10]. Adverse events 
following gentamicin and azithromycin were relatively uncommon; 41 (14%) participants 
had nausea and renal function was not compromised. These data seem to support the role of 
gentamicin 240 mg plus azithromycin 1 g as an alternative regimen for urogenital and 
possibly rectal gonorrhea for persons with cephalosporin allergy.
However, only 82 (80%) of 102 participants with pharyngeal infections were cleared of 
infection, so gentamicin plus azithromycin is not a reliable treatment. Treatment of 
pharyngeal gonorrhea is challenging: pharyngeal infections can be more difficult to eradicate 
than infections at other sites, and the pharynx might serve as a reservoir of asymptomatic 
infection and resistant gonococci [12].
The work by Ross [10] is a welcome step forward. However, because of ongoing 
management challenges and emerging resistance, new drugs with efficacy at all anatomic 
sites are still needed. Pharmacokinetic and pharmacodynamic studies of new drugs are 
needed to understand tissue penetration (especially at extragenital sites) and inform 
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treatment duration. Because few treatment options exist, we might have to re-think existing 
efficacy standards for treatment recommendations.[11] Strengthening prevention programs 
and developing new approaches (including vaccines) are necessary, and staying ahead of the 
threat of gonococcal resistance requires sustained action.
References
1. World Health Organization. Report on global sexually transmitted infection surveillance 2015 
Available at: http://apps.who.int/iris/bitstream/handle/10665/249553/9789241565301-
eng.pdf;jsessionid=A53E316CABDFE86F71B0E3BB5CB084DA?sequence=1. Accessed 13 
November, 2018.
2. Bolan GA, Sparling PF, Wasserheit JN. The emerging threat of untreatable gonorrhea. New Engl J 
Med 2012; 366: 485–487. [PubMed: 22316442] 
3. Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually Transmitted 
Diseases Treatment Guidelines, 2015. MMWR Recomm Rep 2015;64(No. RR-3):1–137.
4. Unemo M, del Rio C, Shafer WM. Antimicrobial resistance expressed by Neisseria gonorrhoeae: A 
major global public health problem in the 21st century. Microbiol Spectrum 
2016;4(3):EI10-009-2015.
5. Eyre DW, Sanderson ND, Lord E, et al. Gonorrhoea treatment failure caused by a Neisseria 
gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, 
February 2018. Euro Surveill. 2018;23(27).
6. Lahra MM, Martin I, Demczuk W, et al. Cooperative Recognition of Internationally Disseminated 
Ceftriaxone-Resistant Neisseria gonorrhoeae Strain. Emerg Infect Dis 2018;24(4):735–743.
7. Taylor SN, Morris DH, Avery AK, et al. Gepotidacin for the Treatment of Uncomplicated 
Urogenital Gonorrhea: A Phase 2, Randomized, Dose-Ranging, Single-Oral Dose Evaluation. Clin 
Infect Dis 2018;67(4):504–512. [PubMed: 29617982] 
8. Taylor SN, Marrazzo J, Batteiger BE et al. Single-Dose Zoliflodacin (ETX0914) for Treatment of 
Urogenital Gonorrhea. N Engl J Med. 2018 11 8;379(19):1835–1845. [PubMed: 30403954] 
9. Kirkcaldy RD, Weinstock HW, Moore PC, et al. The efficacy and safety of gentamicin plus 
azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. Clin 
Infect Dis 2014;59(8):1083–91. [PubMed: 25031289] 
10. Ross JDC, Brittain C, Cole M, et al. Gentamicin compared with ceftriaxone for the treatment of 
gonorrhoea: a randomized trial (G-ToG Trial). Lancet 2019 6 22;393(10190):2511–2520. 
[PubMed: 31056291] 
11. Newman LM, Moran JS, Workowski KA. Update on the management of gonorrhea in adults in the 
United States. Clin Infect Dis 2007;44(Suppl 3):S84–S101. [PubMed: 17342672] 
12. Weinstock HW and Workowski KA. Pharyngeal gonorrhea: an important reservoir of infection? 
Clin Infect Dis 2009; 49(12):1798. [PubMed: 19911969] 
Kirkcaldy and Workowski Page 3
Lancet. Author manuscript; available in PMC 2019 August 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
